Skip to main content

Table 1 Translocation breakpoints mapped to fragile sites in both partner genes of recurrent cancer-specific translocations

From: Over half of breakpoints in gene pairs involved in cancer-specific recurrent translocations are mapped to human chromosomal fragile sites

  5'-b 3'-b  
Translocationa Gene Fragile Site Gene Fragile Site Cancerc
t(2;18)(p11;q21) BCL2 FRA18B IGK@ FRA2L Diffuse large B-cell lymphoma
t(16;16)(p13;q22), inv(16)(p13q22) CBFB FRA16B, FRA16C MYH11 FRA16A Acute myeloid leukemia
inv(10)(q11q21) CCDC6 FRA10C RET FRA10G Papillary thyroid carcinoma
t(11;19)(q13;p13) CCND1 FRA11H FSTL3 FRA19B Chronic lymphocytic leukemia
t(2;7)(p11;q21) CDK6 FRA7E IGK@ FRA2L B-cell lymphoma, Chronic lymphocytic leukemia
t(7;11)(q21;q23) CDK6 FRA7E MLL FRA11B, FRA11G Acute lymphoblastic leukemia
t(5;7)(q35;q21) CDK6 FRA7E TLX3 FRA5G Acute lymphoblastic leukemia
t(12;22)(q13;q12) EWSR1 FRA22B ATF1 FRA12A Soft tissue tumor
t(2;22)(q33;q12) EWSR1 FRA22B CREB1 FRA2I Angiomatoid fibrous histiocytoma
inv(22)(q12q12) EWSR1 FRA22B PATZ1 FRA22B Small round cell tumor
t(6;22)(p21;q12) EWSR1 FRA22B POU5F1 FRA6H Undifferentiated bone tumor
t(2;22)(q31;q12) EWSR1 FRA22B SP3 FRA2G Ewing tumor/small round cell tumor
t(11;22)(p13;q12) EWSR1 FRA22B WT1 FRA11E Soft tissue tumor
del(4)(q12q12)d FIP1L1 FRA4B PDGFRA FRA4B Hypereosinophilic syndrome
inv(6)(p21q21) HMGA1 FRA6H LAMA4 FRA6F Pulmonary chondroid hamartoma
t(3;6)(q27;p21) HSP90AB1 FRA6H BCL6 FRA3C B-cell tumors
t(1;2)(p22;p11) IGK@ FRA2L BCL10 FRA1D B-cell lymphoma
t(2;19)(p11;q13) IGK@ FRA2L BCL3 FRA19A Mature B-cell neoplasm
t(2;3)(p11;q27) IGK@ FRA2L BCL6 FRA3C Mature B-cell neoplasm, Follicular lymphoma
t(2;11)(p11;q13) IGK@ FRA2L CCND1 FRA11A, FRA11H Mature B-cell neoplasm
t(2;18)(p11;q21) IGK@ FRA2L FVT1 FRA18B Follicular lymphoma
t(3;16)(q27;p12) IL21R FRA16E BCL6 FRA3C Diffuse large B-cell lymphoma
t(11;19)(q13;q13.4) MALAT1 FRA11H MHLB1 FRA19A Undifferentiated embryonal sarcoma
t(6;11)(p21.1;q13) MALAT1 FRA11H TFEB FRA6H Pediatric renal neoplasm
t(4;11)(q21.3-22.1;q23) MLL FRA11B, FRA11G AFF1 FRA4F Acute lymphoblastic leukemia, Acute myeloid leukemia
t(2;11)(q11;q23) MLL FRA11B, FRA11G AFF3 FRA2A Acute lymphoblastic leukemia
t(5;11)(q31;q23) MLL FRA11B, FRA11G AFF4 FRA5C Acute lymphoblastic leukemia
del(11)(q23q23)d MLL FRA11B, FRA11G ARHGEF12 FRA11B, FRA11G Acute myeloid leukemia
t(11;11)(q13;q23) MLL FRA11B, FRA11G ARHGEF17 FRA11H Acute myeloid leukemia
del(11)(q23q23)d MLL FRA11B, FRA11G CBL FRA11B, FRA11G Acute myeloid leukemia
t(11;19)(q23;p13) MLL FRA11B, FRA11G ELL FRA19B Acute myeloid leukemia
t(11;22)(q23;q13) MLL FRA11B, FRA11G EP300 FRA22A Acute myeloid leukemia
t(1;11)(p32;q23) MLL FRA11B, FRA11G EPS15 FRA1B Acute myeloid leukemia
t(6;11)(q21;q23) MLL FRA11B, FRA11G FOXO3A FRA6F Acute myeloid leukemia
t(3;11)(q25;q23) MLL FRA11B, FRA11G GMPS FRA3D Acute myeloid leukemia
t(11;14)(q23;q23) MLL FRA11B, FRA11G GPHN FRA14B Acute myeloid leukemia
t(11;19)(q23;p13.3) MLL FRA11B, FRA11G MLLT1 FRA19B Acute myeloid leukemia
t(1;11)(q21;q23) MLL FRA11B, FRA11G MLLT11 FRA1F Acute myeloid leukemia
t(9;11)(p21;q23) MLL FRA11B, FRA11G MLLT3 FRA9A, FRA9C Acute myeloid leukemia
t(11;19)(q23;p13) MLL FRA11B, FRA11G MYO1F FRA19B Acute myeloid leukemia
inv(11)(q14q23) MLL FRA11B, FRA11G PICALM FRA11F Acute myeloid leukemia
t(2;11)(q37;q23) MLL FRA11B, FRA11G SEPT2 FRA2J Acute myeloid leukemia
t(11;19)(q23;p13) MLL FRA11B, FRA11G SH3GL1 FRA19B Acute myeloid leukemia
t(6;11)(q13;q23) MLL FRA11B, FRA11G SMAP1 FRA6D Acute myeloid leukemia
t(10;11)(q21;q23) MLL FRA11B, FRA11G TET1 FRA10C Acute myeloid leukemia
t(9;9)(p21;p21) MTS2 FRA9A, FRA9C MTS1 FRA9A, FRA9C Acute lymphoblastic leukemia
inv(10)(q11q11) NCOA4 FRA10G RET FRA10G Papillary thyroid carcinoma
t(3;5)(q25;q35) NPM1 FRA5G MLF1 FRA3D Acute myeloid leukemia
t(3;6)(q27;p21) PIM1 FRA6H BCL6 FRA3C Diffuse large B-cell lymphoma
t(3;6)(q27;p21) SFRS3 FRA6H BCL6 FRA3C Follicular lymphoma
t(19;19)(p13;q13) TCF3 FRA19B TFPT FRA19A Acute lymphoblastic leukemia
inv(1)(q21q31) TPM3 FRA1F TPR FRA1K Papillary thyroid carcinoma
  1. aThe translocation names for each unique gene set are indicated.
  2. bPosition in which the gene appears in the cancer-specific fusion transcript
  3. cFor a complete description, see the Mitelman database of Chromosome Aberrations in Cancer [27].
  4. dDeletions creating a fusion between two genes
Back to article page

BMC Genomics

ISSN: 1471-2164

Contact us